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Summary
Plasminogen activator inhibitor-1 (PAI-1) is a physiological inhibitor of urokinase (uPA), a serine
protease known to promote cell migration and invasion. Intuitively, increased levels of PAI-1
should be beneficial in down-regulating uPA activity, particularly in cancer. By contrast, in vivo,
increased levels of PAI-1 are associated with a poor prognosis in breast cancer. This phenomenon
is termed the “PAI-1 paradox”. Many factors are responsible for the upregulation of PAI-1 in the
tumor micro-environment. We hypothesize that there is a breast cancer predisposition to a more
aggressive stage when PAI-1 is upregulated as a consequence of Metabolic Syndrome (MetS).
MetS exerts a detrimental effect on the breast tumor microenvironment that supports cancer
invasion. People with MetS have an increased risk of coronary heart disease, stroke, peripheral
vascular disease and hyper-insulinemia. Recently, MetS has also been identified as a risk factor
for breast cancer. We hypothesize the existence of the “PAI-1 cycle”. Sustained by MetS,
adipocytokines alter PAI-1 expression to promote angio-genesis, tumor-cell migration and
procoagulant micro-particle formation from endothelial cells, which generates thrombin and
further propagates PAI-1 synthesis. All of these factors culminate in a chemotherapy-resistant
breast tumor microenvironment. The PAI-1 cycle may partly explain the PAI-1 paradox. In this
hypothesis paper, we will discuss further how MetS upregulates PAI-1 and how an increased level
of PAI-1 can be linked to a poor prognosis.
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Western diet, Metabolic Syndrome (MetS) and breast cancer
“When diet is wrong medicine is of no use. When diet is correct medicine is of no
need.” Ancient Ayurvedic Proverb
Breast cancer is the second leading cause of cancer deaths among women in the United
States. It is predicted that there will be more than 178,000 new cases of invasive breast
cancer and more than 40,000 estimated deaths from breast cancer in 2007.(1) The lifetime
probability of a woman developing breast cancer is 1 in 7.(2) The duration of exposure to
estrogen is a major risk factor for breast cancer.(2) Modifiable risk factors for breast cancer
include obesity, excessive alcohol use and physical inactivity.(2) Invasion and metastasis are
significant hindrances to the effective treatment of women with breast cancer.(3,4) Despite
advances in detection and therapy, many women will return with distant metastases and
eventually succumb to their disease. Understanding the mechanisms that promote or permit
invasion is crucial to the development of effective therapies.
Obesity and the resulting associated metabolic pathologies, now termed Metabolic
Syndrome (MetS), affect more than 50% of adults in the United States. MetS is a group of
metabolic risk factors, including central obesity, dyslipidemia, hyperinsulinemia,
hypertension and prothrombotic/proinflammatory states.(5,6) MetS increases the risk of
coronary heart disease, stroke, peripheral vascular disease and hyperinsulinemia.(7,8) There
is growing epidemiological data to suggest a correlation between high-fat consumption from
a Western diet and breast cancer in humans.(9–11) Recently, it was shown that obesity and
weight gain are associated with increased breast cancer recurrence and cancer
mortality.(12–14)
In the breast, adipocytes are responsible for the synthesis of adipocytokines, potent cellular
modulators upregulated during MetS.(7,8,15–19) Besides adipocytes, there are vascular
endothelial cells and stromal fibroblasts that can be regulated by adipocytokines.(20) In
addition, a prominent feature of MetS is the upregulation of the serine protease inhibitor
(serpin), plasminogen activator inhibitor-1 (PAI-1; systematic name, SERPINE1).(20–23)
PAI-1 is a physiological inhibitor of urokinase-type plasminogen activator (uPA), a serine
pro-tease involved in the promotion of cellular de-adhesion, migration/invasion and
activation of plasmin from plasminogen.(24–27) uPA is upregulated in breast cancer as it
progresses to a metastatic disease. Increased levels of the protease are associated with a poor
prognosis.(28)
Instinctively, one would predict that increased expression of PAI-1 might be beneficial in
breast cancer, since it potently inhibits uPA proteolytic activity. In vitro, PAI-1 has been
shown to inhibit the effects of uPA in cancer.(24–27) However, several clinical studies have
found that increased PAI-1 expression in breast cancer is associated with a grim
prognosis.(3) In the following sections, we present a hypothesis to possibly explain the
relationship of MetS to breast cancer, via a link with PAI-1. We hypothesize that MetS and
adipocytokines alter the microenvironment surrounding the tumor cell by changing the
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expression of various factors, including PAI-1, that promote breast cancer cell migration and
invasion (Figs 1 and 2).
Plasminogen activator system and breast cancer
The plasminogen activator (PA) system plays an important role in promoting tumor cell
invasion.(24–27) uPA is a serine protease involved in many cellular processes including
motility, activation of plasminogen to plasmin and activating pro-matrix metalloproteases
(MMPs). While bound to the urokinase receptor (uPAR), uPA activates the zymogen
plasminogen to the serine protease plasmin at the cell surface. Plasmin activates MMPs and
degrades the surrounding extracellular matrix (ECM).(24–27) Serpins control proteolytic
activity during normal and pathological processes.(29,30) There are four serpins that regulate
the serine proteases of the PA system, PAI-1, plasminogen activator inhibitor-2,
plasminogen activator inhibitor-3 (also known as protein C inhibitor) and α-plasmin
inhibitor. An imbalance in the ratio of protease to the inhibitor allows for increased
degradation of the ECM and increased invasion of tumor cells, which explains why many
components of the PA system are associated with poor prognosis in several types of
cancer.(24–27)
There is an inherent balance among uPA, uPAR and PAI-1 to regulate focal ECM
proteolysis and invasion.(31) However, the known biochemical function of PAI-1 contradicts
its pathological function in cancer. An increased level of PAI-1 would be expected to inhibit
uPA generation of plasmin, protecting the ECM from proteolysis and thus inhibiting
invasion. By contrast, high PAI-1 levels correlate with a poor prognosis and reduced
survival in many cancers including breast cancer.(3) Analyses of pooled data from 18
separate studies showed unequivocally that high levels of PAI-1 and uPA in the tumor are
associated with an increase in relapse and metastasis, and a decrease in survival, indicative
of a poor prognosis in primary breast cancer.(3) Furthermore, a prospective randomized
investigation found that the levels of PAI-1 and uPA in primary breast cancer are predictive
of disease recurrence.(28)
PAI-1 is expressed in many cell types including endothelial cells, fibroblasts, adipocytes,
smooth muscle cells, numerous tissue epithelial cells, keratinocytes, granulosa cells and
platelets. PAI-1 is the primary inhibitor of the PA system targeting both uPA and tissue-type
PA (tPA). PAI-1, in the presence of either VN or heparin, also inhibits the serine protease
thrombin, although the importance of this inhibition reaction in cancer biology is not well
understood. PAI-1 is found in trace levels in peripheral blood because it is a potent uPA and
tPA inhibitor and its latent and protease-complexed forms are rapidly cleared. PAI-1 is
conformationally unstable, rapidly decaying to an inactive form within 1 to 2 hours.(32)
Binding to VN will stabilize PAI-1 for 4 to 6 hours.(33,34) PAI-1 will rapidly inhibit uPA,
which is bound to urokinase receptor (uPAR) on the cell surface. The PAI-1:uPA:uPAR
ternary complex interacts with the low density lipoprotein receptor-related protein (LRP),
which internalizes the quaternary complex.(35) uPAR and LRP will recycle to the cell
surface while PAI-1 and uPA are degraded.(36)
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The “PAI-1 paradox” exists because increased levels of PAI-1, which presumably would
downregulate uPA activity, should be considered good for cancer. However, in vivo, PAI-1
is associated with a poor prognosis in breast cancer. An increase in PAI-1 levels in the breast
tumor environment will affect cell adhesion, migration and invasion, apoptosis and
proliferation, cell signaling and tumor angiogenesis via a mechanism that is partly
independent of its inhibitory site.(24–27,37) We suggest the concept that increased levels of
PAI-1 involve both “traditional” and “non-traditional” roles for PAI-1 in cancer biology.
The hypothesis: PAI-1 cycle
PAI-1 cycle links MetS with breast cancer
We propose that PAI-1 is upregulated as a consequence of MetS. This increase in PAI-1
exerts a detrimental effect on breast tumor cells, adipocytes, stromal fibroblasts and vascular
endothelial cells to promote tumor cell invasion. The “PAI-1 cycle” is sustained by MetS,
resulting in the increased expression of PAI-1 in the tumor microenvironment (Fig. 1). This
PAI-1 will advance numerous pathological processes of breast cancer (Figure 2). However,
we do not presume that all people with MetS will be predisposed to breast cancer.
Adipocytokines, whose production is promoted by MetS, will alter PAI-1
expression.(7,8,18,38–40) The induction of insulin-resistance in adipocytes by MetS will also
sustain PAI-1 expression.(41,42) Increased levels of PAI-1 will support tumor
angiogenesis,(43–45) promote tumor cell adhesion/de-adhesion and activate signaling
pathways to promote tumor cell invasion.(24–27,46,47) PAI-1 will also promote the generation
of pro-coagulant microparticles from endothelial cells. These microparticles can support the
activation of prothrombin to thrombin.(48–50) Thrombin facilitates tumor cell migration by
activating protease-activated receptors to further promote PAI-1 synthesis.(51,52)
Additionally, fibrin produced near the tumor by thrombin will coat the tumor cells,
disguising the tumor from the immune system.(53,54) PAI-1 will also counter act
apoptosis,(55,56) which could increase breast cancer cell survival when treated with a
chemotherapeutic drug. Ultimately, the PAI-1 cycle would provide a chemotherapy-resistant
breast tumor microenvironment primed for invasion/metastasis(55–59) (Figs 1,2). We will
further discuss the various pathophysiological aspects of the PAI-1 cycle and its role in
cancer.
Tumor angiogenesis
PAI-1 has been shown to be both pro-angiogenic and anti-angiogenic. PAI-1 –/– mice,
described by Devy et al(60) and McMahon et al,(61) have a reduction in angiogenesis, up to
60%,(61) compared to wild-type mice. Addition of wild-type (wt)-PAI-1 at physiological
concentrations, up to 1 nM, restores/increases angiogenesis up to 3-fold, as seen in two
different angiogenic assays,(60,61) while wt-PAI-1 above 1 to 2 nM reduces angiogenesis in
these same assays.(60,61)
How PAI-1 affects angiogenesis is not fully understood. Adenoviral gene transfer of wild-
type and mutant forms of PAI-1 that either bind ineffectively to vitronectin (VN) or are
unable to inhibit the PA system show angiogenesis is promoted through PAI-1 inhibition of
uPA and tPA.(60,62) uPA and tPA activate plasminogen to plasmin. Excessive plasmin
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activity could lead to vessel destabilization.(62) Others have shown that the interaction of
PAI-1 with the surrounding ECM is a key parameter affecting the progression of
angiogenesis. In neuroblastoma tumors, PAI-1 co-expresses with integrins, specifically
αvβ3, on endothelial cells.(63) PAI-1 binds to VN and prevents VN-integrin cell interactions,
resulting in endothelial cell migration towards fibronectin.(63)
Cell adhesion and proliferation
The PA system is involved in both promoting and preventing cell adhesion. Cells can bind
VN through integrins, such as αvβ3 and uPAR.(64,65) uPAR on the cell surface binds directly
to VN(65,66) and this interaction will upregulate integrin binding to the ECM. uPA bound to
uPAR also promotes the interaction of uPAR to VN and strengthens cell adhesion to the
ECM.(67,68) Occupied uPAR will also associate with integrins to further strengthen the cell’s
adhesion to VN [reviewed in Refs 69,70].
PAI-1 inhibits PA-system-mediated cell adhesion by disrupting the interactions of uPAR
and integrins with the ECM.(64,65,71) PAI-1 competes with uPAR for VN binding.(65)PAI-1
will lose the ability to bind to VN when it complexes with uPAR-bound uPA.(65,72) PAI-1
inhibition of uPA prevents the serpin from interacting with the cell and ECM, promoting cell
adhesion to VN, fibronectin and laminin.(73) By removing PAI-1 from VN, cell adhesion is
promoted through integrin interaction with the ECM. PAI-1 inhibition of uPA can also
promote cell de-adhesion. Internalization of the integrin:uPAR:uPA:PAI-1 complex by LRP
removes key components needed to adhere the cell to the ECM.(74)
We have found that overexpressing wild-type PAI-1 (wt-PAI-1) in the MDA-MB-435 cells,
a breast cancer cell line, decreased the rate of proliferation when compared to either parental
cells or the inactive mutant P14 PAI-1-expressing MDA-MB-435 cells (P14 is T333R
PAI-1).(73,75,76) Anchorage-dependent colony-forming efficiency was used as a measure of
cell proliferation. The wt-PAI-1-expressing MDA-MB-435 cells had a decreased ability to
form colonies compared to the parental, Neomycin vector control and P14-PAI-1-expressing
MDA-MB-435 cells (Table 1). Anchorage-independent proliferation, a hallmark of
metastatic potential, had similar results. wt-PAI-1-expressing MDA-MB-435 cells had a
reduced ability to form colonies in soft agar when compared with the other MDA-MB-435
cells (Table 1). Although PAI-1 has been associated with a negative prognosis in breast
cancer, these results show it to be a negative regulator of proliferation of breast cancer cells
in vitro.
A possible explanation for the decrease in proliferation by PAI-1 may be through an
established function of the cell signaling protein, Akt. Akt is involved in cell survival and
proliferation [reviewed in Ref. 77]. PAI-1 –/– endothelial cells have an increased level of
phosphorylated Akt and an increased rate of proliferation.(78) wt-PAI-1-expressing
MDAMB-435 cells have less phosphorylated Akt compared to inactive P14-PAI-1-
expressing MDA-MB-435 cells, parental MDA-MB-435 cells and Neomycin vector control
MDA-MB-435 cells (data not included). Our laboratory and others have recently shown that
PAI-1 levels are increased in cells that have had the phosphatidylinositol 3-kinase/Akt-Akt
signaling axis inhibited.(42,79) Why a negative indicator of breast cancer survival slows
Beaulieu et al. Page 5






















down cell proliferation is not fully understood. It is possible that PAI-1 may serve in a
protective role; thus, slowing tumor cell growth could permit more genetic alterations to
occur advancing breast cancer to a metastatic stage.
Cell migration and invasion
All components of the PA system are involved in regulating cell migration and invasion.
These interactions of the PA system can be complex, cell-type-specific and often context
specific. uPA stimulates migration of breast cancer cells, dependent on uPAR ligation and
subsequent activation of cell signaling pathways by integrins.(80,81) There is a reduction in
tumor cell migration and metastasis when uPA is inhibited by PAI-1. When uPA is
overexpressed, altering the ratio of protease to inhibitor, cell migration in vitro is
promoted.(82)
PAI-1 has been shown to promote cell migration. Chazaud et al(83) showed PAI-1 attaches
to cells through uPA:uPAR, which alters cell morphology and promotes breast cancer cell
migration. This increase in migration can only occur when all of the components of the PA
system are present.(83) wt-PAI-1-expressing MDA-MB-435 cells are shown to have
significantly increased chemotaxis to VN and fibronectin compared to control cells.(73)
Alternatively, PAI-1 can support cell migration by preventing cell adhesion to VN.(67,84) In
smooth muscle cells, PAI-1 increases migration by binding to LRP, which results in
morphology changes, cytoskeleton reorganization and alterations in signaling pathways.(85)
PAI-1 also inhibits tumor cell migration.(72,75,86–88) HT1080 cells expressing wt-PAI-1 have
reduced cell migration in vitro and do not form many lung metastases in vivo.(82) The same
is true in glioma cells expressing PAI-1 with a reduction in invasion in vitro compared to
wild type.(84) Overexpressing PAI-1 in breast and ovarian cancer cells reduces both cell
migration and invasion, dependent on the active form of PAI-1.(75) PAI-1 will complex with
uPA and through the formation of a ternary complex with uPAR, will also bind LRP. This
quaternary complex is internalized resulting in a loss of components of the PA system and
reduction in cell migration.(88) Treatment with either receptor-associated protein (RAP), a
LRP-binding protein that competitively inhibits ligand binding, or LRP-blocking antibodies
reverses these effects on migration. However, PAI-1-mediated inhibition of migration can
also be independent of its uPA-inhibitory role. A mutant form of PAI-1 that is unable to
inhibit uPA also prevented cell migration by disrupting the interactions of VN and
integrins.(72) Smooth muscle cell migration can also be inhibited in the presence of PAI-1
through the disruption of VN binding to the cell.(87)
Apoptosis and the gene expression profile of PAI-1-expressing cells
Components of the PA system may regulate apoptosis. PAI-1 has been shown to inhibit
apoptosis when added exogenously to both normal and tumor cells, again, due to its
inhibition of uPA.(55) This fact alone might explain the PAI-1 paradox. Excess PAI-1
protects cancer cells from apoptosis. As a result, PAI-1 could promote the formation of a
more aggressive tumor. A closer examination of PAI-10s inhibition of apoptosis showed that
PAI-1 inhibits caspase-3-mediated apoptosis in vascular smooth muscle cells.(56)
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Slower proliferating cells tend to have a decreased sensitivity to chemotherapeutic
agents.(89) We believe that endogenously produced PAI-1 confers a “survival advantage”
upon cancer cells. It has been shown that the disruption of the cytoskeleton with
chemotherapeutic drugs will alter the balance of protease-to-protease inhibitor in favor of
PAI-1.(90) PAI-1 expression is affected by the perturbation of the actin cytoskeleton by
cytochalasin D.(57,58) Although multiple chemotherapeutic drugs are used to treat breast
cancer, paclitaxel (Taxol) has shown efficacy in patients with drug resistance cancers,
including breast cancer.(91) In our studies with the PAI-1-expressing MDA-MB-435 cells,
paclitaxel initially induces cell death in both wt-PAI-1-expressing and P14-PAI-1-
expressing MDA-MB-435 cells (data not shown). However, when the cells were allowed to
recover for 48 hours after treatment in complete medium, wt-PAI-1-expressing MDA-
MB-435 cells had an increase in survival compared to P14-PAI-1-expressing MDA-MB-435
cells, although when plated onto either vitronectin or fibronectin surfaces the increase in
survival between cell types was less different (data not included). These results imply that
PAI-1 increases cell survival that depends on the integrity of the inhibitory site.
The upregulation of PAI-1 in a cancer cell is clearly conducive to promoting tumor cell
progression to a malignant state. A cDNA microarray analysis was done on RNA extracted
from the PAI-1-expressing MDA-MB-435 cells compared to the parental and vector control
MDA-MB-435 cells. Of those genes, a list was generated of genes that were upregulated
≥2.5 or downregulated ≥0.5 compared to the MDA-MB-435 Neo cells (Table 2). Of the 23
genes upregulated in the wt-PAI-1-expressing MDA-MB-435 cells, many are associated
with adhesion, motility and angiogenesis, thereby bringing nutrients to the tumor and
providing a means for metastasis to occur. PAI-1 expression reduces cell proliferation by
both upregulating genes associated with senescence (G protein-coupled receptor 1) and
downregulating genes associated with promoting proliferation. These results agree with
what has been published about the effects of PAI-1 on cancer.
PAI-1 expression in the MDA-MB-435 cells increases the expression of genes that are
typically upregulated in various cancers, including breast cancer (Table 2). ELAV results in
unstable mRNA in breast cancer(92) and eta polypeptide, a 14-3-3 protein involved in
various signal transduction pathways, binds to gremlin 1, which is upregulated in numerous
cancers, including breast cancer.(93)
Two genes that were upregulated in the wt-PAI-1-expressing MDA-MB-435 cells would
make the cells more responsive to stimuli produced by the MetS (Table 2). Protein
phosphatase 2C, magnesium-dependent, catalytic subunit is a mitochondrial enzyme
regulated by insulin.(94) Niemann-Pick disease, type C1 is a lysosomal membrane protein
involved in cholesterol trafficking,(95) and, most importantly, in drug resistance by its drug
efflux and sequestration.(96)
The genes downregulated in the wt-PAI-1-expressing MDA-MB-435 cells were less
numerous (Table 2). These genes are associated with proliferation, differentiation and
adhesion. Apolipoprotein D regulates both proliferation(97) and cell migration.(98) Follistatin
is typically downregulated in cancer and is an inhibitor of anti-proliferative pathways.(99) G
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protein-coupled receptor 126, which is associated with adhesion,(100) is also downregulated
by PAI-1 expression.
Conclusion
“What is food to one man may be fierce poison to others.” Lucretius (99 B.C.-55
BC).
Obesity is a worldwide problem that contributes to the risk and prognosis of many cancers,
including breast cancer. With a high-caloric and high-fat Western diet, the resulting MetS
will enhance the synthesis of PAI-1 and other components of the PA system in the tumor
microenvironment. Adipocytokines (insulin, insulin-like growth factor 1, tumor necrosis
factor-alpha, interleukin-6 and leptin/adiponectin) and other by-products of MetS (such as
glucose and cholesterol) will alter PAI-1 expression not only in breast tissue adipocytes and
in endothelial cells but also in breast cancer cells to potentially favor invasion and
metastasis. The complex role and interaction between obesity and MetS linked to PAI-1
expression will clearly be studied for many years to come, as many study the pathological
consequences of increased levels of PAI-1.
We hypothesize that increased expression of PAI-1 and other components of the
plasminogen activator system (uPA and uPAR) confers a survival advantage upon breast
cancer cells by decreasing sensitivity to chemotherapeutic agents, regulating adhesion,
increasing tumor angiogenesis and increasing cell migration (Figs 1,2). As many researchers
and clinicians have been and are still trying to fully understand the role of PAI-1 in cancer,
the PAI-1 cycle hypothesis may further explain the paradox as to why a protease inhibitor of
ECM degradation is detrimental for women with breast cancer (Fig. 2).
Acknowledgments
We thank Ms. Jessica Polka for her artistic interpretation of the PAI-1 cycle.
Abbreviations
ECM extracellular matrix





breast cancer cell line, MDA-MB-435, expressing a mutant
PAI-1, which has a Thr replaced at position 333 with an Arg
PA plasminogen activator
PAI-1 plasminogen activator inhibitor-1
PAI-1–/– PAI-1 knockout
RAP receptor-associated protein
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uPA urokinase-type plasminogen activator
uPAR uPA receptor
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Breast cancer, MetS and the PAI-1 cycle.
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Metastatic breast cancer and the PAI-1 cycle. Adipocytokines as a consequence of MetS will
increase PAI-1 expression in breast adipocytes and surrounding tumor microenvironment.
The increased levels of PAI-1 will support tumor angiogenesis, promote tumor cell
adhesion/de-adhesion and activate signaling pathways to promote tumor cell invasion. PAI-1
will promote the generation of procoagulant microparticles from endothelial cells and
thrombin will further promote PAI-1 synthesis. Fibrin will coat the tumor cells to help the
tumor cells avoid immune surveillance. PAI-1 will also counteract apoptosis to provide a
chemotherapy-resistant breast tumor microenvironment. Ultimately, the PAI-1 cycle will
lead to sustained PAI-1 synthesis.
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Table 1
Stable Expression of wt-PAI-1 Decreases MDA-MB-435 Cell Proliferation
a
MDA-MB-435 Cell type Anchorage-dependent proliferation (% CFE) Anchorage-independent proliferation (%CFE)
Parental 100 ± 5 100 ± 6






P14-PAI-1-expressing 121 ± 9 113 ± 10
a
MDA-MB-435 cells PAI-1-expressing [wildtype (wt) and inactive T333R (P14)] and control MDA-MB-435 cells were generated as described
previously.73,75,76 For anchorage-dependent proliferation, cells were plated at 50 cells per 60 mm2 dish in 3 ml growth media and grown for 14
days. Colonies were fixed in 3:1 methanol:acetic acid and stained with Giemsa. Colonies of >50 cells were counted and expressed as a % of the
number of colonies in the parental MDA-MB-435 population to yield colony-forming efficiency (CFE). For anchorage-independent proliferation,
soft agar assays were performed by plating 20,000 cells per 60 mm2 dish. Cells were suspended in a thin layer of 0.33% noble agar, which was
overlaid on a 0.5% agar layer containing 10% FBS in 2× MEM. CFE's were assessed after 3 weeks by counting colonies with >50 cells. The data




p < 0.01, compared with the parental MDA-MB-435 cells.
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